Posted in In The News on Oct 07, 2016
Eric Luellen of Boston is the founder of Bioinformatix’s Rx&You, a cloud-based artificial intelligence platform designed to address four distinct problems impacting clinical outcomes today: medication non-adherence, coordination of care, drug-drug interactions, and patient education...
Posted in In The News on Oct 02, 2016
We have featured examples of CEP applied to the medical field in past articles here, and in our books. The one deployed in Rx&You is new to us. The combination of AI and CEP to develop a drug event system that screens for drug interactions in real time and issues alerts etc. is innovative. It offers an interesting opportunity to develop standards for event abstraction hierarchies for this area of medical monitoring.
Posted in In The News on Sep 29, 2016
Rx&You Voted Audience Favorite for C3 Prize @StanfordMedX
Posted in In The News on Sep 25, 2016
This past April, Astellas Oncology launched the C3 Prize, a challenge aimed at inspiring novel, non-treatment and non-medicine based ideas to change cancer care. The judges included Mark Reisenauer, SVP of the Oncology Business Unit for Astellas Pharma US; Robert Herjavec, IT Entrepreneur, Founder & CEO of the Herjavec Group and star of ABC’s “Shark Tank”; Chris Coburn, Vice President of Innovation at Partners HealthCare and host of the World Medical Innovation Forum; and Michael Seres, who is ePatient-in-Residence and Executive Board Member for Stanford Medicine X. Five finalists pitched at t...
Posted in In The News on Sep 19, 2016
The past weekend we spent at Stanford Medicine X, listening to interesting and inspiring talks, and interacting with a diverse group of people and the ideas they brought with them. The event is designed to bring people from all aspects of medical care, including doctors and nurses, patients and caretakers, insurance reps, hospital administrators, policy makers, product designers, and many others. It was somewhat overwhelming, but because different rooms were used to host presentations in parallel we were able to choose which discussions to attend.
Posted in In The News on Sep 12, 2016
Bioinformatix has been selected as one of five finalists for the Astellas Oncology's C3 Prize.